Science RSS Feeds
Boeing Co, facing its biggest crisis in years following deadly crashes of its flagship 737 MAX aircraft, has brought in a new vice president of engineering while dedicating another top executive to the aircraft investigations, a company email showed on Tuesday. The management reshuffle comes as Europe and Canada said they would seek their own guarantees over the safety of Boeing's 737 MAX, further complicating plans to get the aircraft flying worldwide after they were grounded in the wake of crashes that killed more than 300 people. John Hamilton, formerly both vice president and chief engineer in Boeing's Commercial Airplanes division, will focus solely on the role of chief engineer, the unit's Chief Executive Officer Kevin McAllister told employees on Tuesday in an email seen by Reuters.
Aspirin is out. Here's how healthy older adults can prevent heart attacks, strokes without pills
One of NASA's most exciting ongoing missions is that of the InSight lander that currently calls Mars home. The robotic lander has the potential to teach scientists a great deal about the Red Planet and its history, but first NASA has to figure out what to do with one of its important, but underperforming, instruments.The tool, which is described as a "self-hammering mole" is designed to dig several meters into the planet in order to take temperature readings and paint a more complete picture of what is going on deep inside. Unfortunately the instrument's first attempt fell well short of expectations, and its engineers aren't sure why.As SpaceNews reports, the German team behind the self-burrowing instrument recently discussed the tool's failure, expressing confusion over the result."At about 30 centimeters depth we encountered something," Tilman Spohn of the German space agency DLR reportedly said. "We don't know yet if it's a harder layer of regolith or a rock."At this point it's not clear if the tool rand smack dab into the middle of a rock or if the instrument itself experienced some sort of problem. The tool only managed to reach a depth of just shy of one foot, but the plan was to have it dig as deep as 16 feet. Needless to say, that's one heck of a shortfall, and the scientists would love to know why.Going forward, the team plans to capture images of the instrument using the lander and relay them back to Earth. The idea is to see if there's an obvious problem with the tool, and if everything seems okay they'll have to assume they simply ran into a rock or some other impenetrable object.The team plans on taking another crack at digging within a few weeks, and hopefully that attempt will result in a deeper hole.
Now investors who want a piece of America’s second-largest ride-hailing company will likely need to pay a premium when the stock starts trading next week. The San Francisco-based company has only been on the road marketing its initial public offering for two days, but investors have already been informed that the listing is oversubscribed at the current price range, said people familiar with the matter, who asked not to be identified because the details are private. Lyft is expected to price its shares on March 28 and begin trading on the Nasdaq the next day.
Microsoft Corp. co-founder Bill Gates, once the world’s richest person, has again eclipsed the $100 billion threshold, joining Amazon.com Inc.’s Jeff Bezos in the exclusive club, according to the Bloomberg Billionaires Index. Gates’s fortune, now $100 billion on the nose, hasn’t reached such heights since the dot-com boom, when Bezos was only beginning his march up the world’s wealth rankings. The Amazon founder is now worth $145.6 billion, having added $20.7 billion this year alone, while Gates has gained $9.5 billion.
Matt Hancock has revealed that he is at heightened risk of developing prostate cancer as he urges the NHS to roll out gene testing more widely. The Health Secretary said he has undergone tests which show that he has a higher rate of the disease than the average man, despite no family history of the cancer. Mr Hancock called for a national debate about the biggest ethical questions concerning a revolution in genomics, as he revealed that he was shocked by his own results. The tests found he has a 15 per cent chance of suffering prostate cancer by the age of 75 - a risk about 1.5 times greater than the average man. In a speech to The Royal Society, the Health Secretary will say the test may have saved his life, as he called for the urgent rollout of “predictive testing” across the NHS. Mr Hancock is expected to say that too much data was “locked away” in research labs, as a result of bureaucratic obstacles and scientists refusing to share it. He will also call it an “outrage” that findings which could save lives were not more widely shared, urging researchers to “publish or be damned”. The Health Secretary, who is 40, has recently undergone a number of tests, to examine his own genes. He will tell the event that he was glad to find that for most of 16 diseases tested, he had a lower risk than average. “I probably have my grandmother, who lived to a 103, to thank for that,” he is expected to say. But he said he was left “surprised and concerned” when he was found to be at higher risk of prostate cancer. Mr Hancock will say he plans to discuss the results with his GP, and would be certain not to miss any screening checks for the disease, which is highly treatable if caught early. “I would never have found this out if it hadn’t been for the genomic test. Tragically, so many men don’t find out they have it, until it’s too late. The truth is this test may have saved my life,” he will say, calling on services to “get predictive testing into the NHS as soon as we possibly can.” Currently the NHS offers limited gene testing, when patients are thought to be at higher risk, because of a family history of disease. Mr Hancock will say too much data is “locked away in research labs” as a result of bureaucracy, or because scientists do not want to share their findings. “Data, funded by the British taxpayer, donated by the public, can’t be used for predictive testing because of bureaucratic blocking or a scientist wanting to have a monopoly: that’s an outrage,” he will say. “We will unlock that data. Because we must save lives. And I say this to any researcher, who is blocking data access: open up this data, publish or be damned.” The Government has set out an ambition to sequence 5 million genomes over the next five years to build a diagnostic, predictive, preventative and personalised health and care service. So far 100,000 genomes have been sequenced, allowing one in four participants with rare diseases receiving a diagnosis for the first time.
Presenting results of a large international study conducted in one in site Brazil and across 11 sites in Europe – including in Amsterdam, London and Paris – the researchers found that people who used cannabis daily were three times more likely to have an episode of psychosis than people who had never used it. Skunk contains more THC, or delta-9-tetrahydrocannabinol, than regular cannabis, and THC can induce psychotic symptoms such as hallucinations, delusions and paranoia. The study found the link between cannabis and psychosis was strongest in London and Amsterdam, where high potency skunk is commonly available.
A jury has found one of the world’s most widely-used weed killers to have been a “substantial factor” in causing a man’s cancer. The unanimous decision, made after five days of deliberations in San Francisco’s federal court, found that Roundup, Bayer AG’s weed killer, was responsible for California resident Edwin Hardeman’s non-Hodgkin lymphoma. It instead allows the trial to proceed to a second phase, which will determine the company’s potential liability and damages.
In his annual “Energy Outlook” report, Michael Cembalest, chairman of market investment and strategy for the asset management group, wrote that the U.S. needs to reduce its use of carbon much faster -- a view he shares with the authors of the Green New Deal, including first-term Democratic Representative Alexandria Ocasio-Cortez of New York. “People are not getting the full picture about what’s feasible,” Cembalest said in a phone interview Tuesday.
Many of NASA's satellites spend their entire lives pointed deep into the cosmos, but the space agency also had plenty of lenses pointed back down towards Earth. NASA tracks all kinds of things that happen here on our planet, including weather systems and natural disasters like the record-setting floods currently taking place in Nebraska.In a new series of images, NASA's Landsat 8 satellite shows how dramatically much of Nebraska has changed as flood waters turned otherwise calm waterways into lake-sized bodies of water spilling into populated areas. The following before-and-after photos were snapped a year apart.March 2018:March 2019:The flooding has resulted in several evacuation orders across a wid area, primarily affecting communities near the river system that includes the Missouri river and Elkhorn river. As NASA explains, a variety of things contributed to the record-breaking water levels."A rare confluence of circumstances produced the flooding," NASA writes in a new blog post. "Extreme cold earlier in the winter set the stage by preserving a significant amount of snow; it also created a thick layer of ice on waterways and made the ground less permeable than usual. When an intense storm brought downpours and unusually warm air to the region in March, it rapidly melted much of the snow and ice, producing enormous runoff in a short period."On top of that, river ice piled up in many areas, causing water to back up to even higher levels. Plenty of farmland was flooded as a result, but the primary concern was of course the riverside communities. Many homes and businesses were flooded, and some areas even became islands in the middle of raging river waters.
The drug, which is administered as a single 60-hour intravenous infusion, is chemically identical to the hormone allopregnanolone. "You're talking about someone coming into the hospital or treatment center on a Friday and go home Sunday night," Sage's Chief Executive Officer Jeff Jonas told Reuters ahead of the approval. Postpartum depression, an extreme form of the so-called baby blues, affects one in nine women and is a common complication of childbirth, with onset typical during pregnancy or within four weeks of delivery.
The finding by the unanimous jury in San Francisco federal court clears the way for that same jury to determine if Bayer unit Monsanto is liable and must pay damages to California resident Edwin Hardeman in a second trial phase. Bayer in a statement on Tuesday said it was disappointed with the jury's initial decision. "We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and the company should not be liable for Mr. Hardeman's cancer," the company said.
Federal jury’s decision in case of man who said he used weedkiller for decades could affect hundreds of other plaintiffsThe decision in Edwin Hardeman’s case comes after a historic verdict last year that said Roundup caused another man’s terminal cancer. Photograph: Josh Edelson/AFP/Getty ImagesA federal jury in San Francisco found Monsanto’s Roundup herbicide was a substantial factor in causing the cancer of a California man, in a landmark verdict that could affect hundreds of other cases.Edwin Hardeman of Santa Rosa was the first person to challenge Monsanto’s Roundup in a federal trial and alleged that his exposure to Roundup caused him to develop non-Hodgkin’s lymphoma (NHL), a cancer that affects the immune system.In the next phase of the case, the jury will weigh liability and damages, and Hardeman’s lawyers will present arguments about Monsanto’s influence on government regulators and cancer research.During the trial, the 70-year-old Santa Rosa man testified that he had sprayed the herbicide for nearly three decades and at one time got it on his skin before he was diagnosed with cancer. He used the chemical to control weeds and poison oak on his properties, starting in 1986.Hardeman’s case is considered a “bellwether” trial for hundreds of other plaintiffs in the US with similar claims, which means the verdict could affect future litigation and other cancer patients and families. Monsanto, now owned by the German pharmaceutical company Bayer, is facing more than 9,000 similar lawsuits across the US.The unanimous ruling on Tuesday follows a historic verdict last August in which a California jury in state court ruled that Roundup caused the terminal cancer of Dewayne Johnson, a former school groundskeeper. That jury said Monsanto failed to warn Johnson of Roundup’s health hazards and “acted with malice or oppression”, awarding Johnson $289m in damages.Hardeman’s trial has been more limited in scope. While Johnson’s attorneys argued that Monsanto had “bullied” scientists and fought to suppress negative studies about its product, the federal judge barred Hardeman’s lawyers from discussing Monsanto’s alleged influence on research and regulations during the hearings.The US judge Vince Chhabria went so far as to sanction Hardeman’s lawyer for bringing up Hardeman’s “personal history”, referring to internal Monsanto documents, and explaining the process behind various regulatory decisions about glyphosate in her opening remarks. With Hardeman’s trial limited to a strict discussion of whether Roundup exposure caused his cancer, his attorneys have argued they were facing a significant disadvantage.Monsanto has continued to argue that Roundup is safe to use and does not cause NHL.Although the judge restricted the first part of the trial to a limited discussion of Hardeman’s cancer, he issued something of a rebuke of the company in one procedural order last week, saying: “Although the evidence that Roundup causes cancer is quite equivocal, there is strong evidence from which a jury could conclude that Monsanto does not particularly care whether its product is in fact giving people cancer, focusing instead on manipulating public opinion and undermining anyone who raises genuine and legitimate concerns about the issue.”Bayer expects to prevail later in the trial, a spokesperson said following Tuesday’s ruling. “We are disappointed with the jury’s initial decision, but we continue to believe firmly that the science confirms glyphosate-based herbicides do not cause cancer”, spokesman Dan Childs said in a statement. “We are confident the evidence in phase two will show that Monsanto’s conduct has been appropriate and the company should not be liable for Mr Hardeman’s cancer”.Child also argued the decision would not impact future cases, “because each one has its own factual and legal circumstances”.Jennifer Moore and Aimee Wagstaff, Hardeman’s attorneys, said they were prepared to show the jury examples of Monsanto’s “bad conduct” in the next phase of the trial. “Now we can focus on the evidence that Monsanto has not taken a responsible, objective approach to the safety of Roundup”, they wrote in a statement.Environmental advocates were quick to celebrate the verdict. Ken Cook, the president of the Environmental Working Group, said the ruling supported previous conclusions that “glyphosate causes cancer in people”.“As similar lawsuits mount, the evidence will grow that Roundup is not safe, and that the company has tried to cover it up”, he added.
The stock rallied 12 percent Tuesday as Google unveiled its video-game streaming service that will use AMD processors, even though analysts said the chipmaker’s involvement was already known. AMD Chief Executive Officer Lisa Su said during a presentation at the CES trade show in January that its graphics processors would be used as part of Google’s gaming project. “We are surprised by the stock price move as we believed this was a well known win,” RBC’s Mitch Steves wrote in a research note after Google’s presentation.
The weedkiller Roundup was a "substantial factor" in the cancer of a US man who developed a lump in his throat after decades of spraying his garden -- the second major legal defeat to agrochemical giant Monsanto in a year. Edwin Hardeman, 70, treated his property in Sonoma County, California, regularly with the herbicide from 1980 to 2012 and was eventually diagnosed with non-Hodgkin's lymphoma. "Now we can focus on the evidence that Monsanto has not taken a responsible, objective approach to the safety of Roundup," they added.
NIH Funding Opportunities
- Notice of Correction to Application and Submission Information for PAR-18-543 "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)"
- National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32)
- Notice of Clarification to the Award Budget for PAR-18-894, "Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)"
- Notice of Intent to Publish a Funding Opportunity Announcement for the NIH Common Fund Acute to Chronic Pain Signatures Program: Multisite Clinical Center Acute Pain from Musculoskeletal Trauma or Acute Peri-operative Pain (UM1 Clinical Trial Optional)
- Notice of Change to the Award Budget for PAR-18-802 "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)".